Two market leaders join forces to meet the growing demand for high-quality histopathology and neuropathology services in the preclinical therapeutics market
MT. JACKSON, VA and FREDERICK, MD (USA) – April 10, 2019 – StageBio has merged with Tox Path Specialists, LLC (TPS) to create the leading provider of research and preclinical histology, pathology, specialized neuropathology and archiving services for the biopharmaceutical, medical device and contract research industries. StageBio was recently created by the merger of Histo-Scientific Research Laboratories (HSRL) and Vet Path Services (VPS) and is a portfolio company of Ampersand Capital Partners.
“We are very excited to merge operations with Dr. Mark Butt and his team at Tox Path Specialists as we continue to broaden our service offerings to both new and existing clients,” said Tom Galati, StageBio CEO. “It is our intent to position StageBio as the most capable histopathology company in the industry”.
Dr. Mark Butt, Founder & CEO of Tox Path Specialists, commented, “StageBio and TPS are a natural fit. The broad spectrum of histopathology services of StageBio coupled with our specialty neuropathology capabilities are a great match and will further streamline the research process for our clients”. The merger adds laboratory space in Frederick, MD, and more importantly adds staff with vast experience in specialty neuropathology techniques to complement the StageBio team based in Virginia, Ohio and Massachusetts. The combined business has over 20 board-certified pathologists and a total employee base of over 100.
StageBio is the leading provider of GLP-compliant research and preclinical histology, pathology and specimen archiving services for the biopharmaceutical, medical device and contract research industries. We provide our customers with a fully-integrated breadth of histopathology services, including tissue analysis, efficacy determination for new compounds and devices, toxicological evaluation of products subject to FDA approval, detailed pathology reporting for GLP studies, medical device pathology and immunohistochemistry. We operate four state-of-the-art sites in the US, with substantial continued investment in our facility and technology infrastructures to meet the growing demand for high-quality histopathology services. With more than 20 board-certified veterinary pathologists and over 50 laboratory technicians on staff, we are ideally positioned to deliver on our unified commitment to quality, scientific integrity and customer service excellence. Additional information about StageBio is available at www.stagebio.com.
About Tox Path Specialists
Founded in 2006, TPS is one of the leading neuropathology laboratories in North America. Founded and led by Dr. Mark Butt, TPS specializes in comprehensive evaluations of the central and peripheral nervous system. TPS is a full-service GLP histopathology laboratory, offering expertise in histology, pathology immunohistochemistry, image analysis and stereology. Its staff consists of 2 board-certified (ACVP) veterinary pathologists, 6 highly-trained histology technicians as well as dedicated Quality Control (QC) and Quality Assurance (QA) units, all of whom are committed to quality work, excellent customer service and meeting demanding timelines. Additional information about TPS is available at www.toxpath.net.
About Ampersand Capital Partners
Founded in 1988, Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of its core healthcare sectors, including Brammer Bio, Confluent Medical, Genewiz, Genoptix, Talecris Biotherapeutics and Viracor-IBT Laboratories. Additional information about Ampersand is available at www.ampersandcapital.com.
For further information contact:
Director of Corporate Development